🧬 Endocrinology Update: Cushing’s Drug Progress, AI in Care, Menopause Therapy Reexamined and More
From drug innovations and AI disruption to surprising cancer risks and tech that could change diagnostics—this update covers the most critical developments shaping the future of endocrine care.
đź“Ś In This Episode:
💊 Relacorilant shows major metabolic gains in Cushing’s Syndrome Phase III trials—FDA decision expected by end of 2025.
🔄 FDA reopens review on hormone therapy for menopause; boxed warning removals gain momentum.
🧠Empathy-driven phone support reduces HbA1c by up to 1.1%—non-clinical staff lead scalable diabetes care.
🔬 Human trial begins for thyroid device that may eliminate unnecessary surgeries for Bethesda IV nodules.
⚠️ Acromegaly patients face up to three-point-three times higher risk for ovarian, lung, and blood cancers.
🧬 FAK enzyme drives thyroid cancer metastasis—new therapeutic target in development.
🤖 AI tools are revolutionizing chronic endocrine care—diabetes, PCOS, and obesity personalization expands.
🧪 Sanofi’s dual-action T1D therapy enters Phase 2a—aims to preserve beta-cell function with results expected in 2026.
🔍 Machine learning predicts eczema flares based on duration and frequency—shaping future treatment plans.
📉 Lexicon’s diabetes pipeline gains traction with sotagliflozin and pilavapadin—yet remains undervalued despite $310M in cash reserves.
📢 Stay Ahead in Endocrinology Research!
âś… Like, share, and subscribe for weekly updates on endocrinology, diabetes, thyroid health, and more.
#endocrinology #CushingsSyndrome #DiabetesCare #HormoneHealth #ThyroidCancer #AIinHealthcare #Type1Diabetes #Eczema #LexiconPharma #LQVentures #MedicalInnovation #ClinicalResearch #Sanofi #HealthcareTech